These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 1396108)
21. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre. Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243 [TBL] [Abstract][Full Text] [Related]
23. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Rosado J; Walsh SL; Bigelow GE; Strain EC Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480 [TBL] [Abstract][Full Text] [Related]
24. The implementation of buprenorphine/naloxone in college health practice. DeMaria PA; Patkar AA J Am Coll Health; 2008; 56(4):391-3. PubMed ID: 18316282 [TBL] [Abstract][Full Text] [Related]
25. Buprenorphine in combination with naloxone at a ratio of 15:1 does not enhance antinociception from buprenorphine in healthy cats. Slingsby LS; Murrell JC; Taylor PM Vet J; 2012 Jun; 192(3):523-4. PubMed ID: 22030474 [TBL] [Abstract][Full Text] [Related]
34. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder. Becker WC; Ganoczy D; Fiellin DA; Bohnert AS J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475 [TBL] [Abstract][Full Text] [Related]
35. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Comer SD; Walker EA; Collins ED Psychopharmacology (Berl); 2005 Oct; 181(4):664-75. PubMed ID: 16025322 [TBL] [Abstract][Full Text] [Related]
36. Effects of naloxone, diprenorphine, buprenorphine and etorphine on unpunished and punished food-reinforced responding in the squirrel monkey. DeRossett SE; Holtzman SG J Pharmacol Exp Ther; 1984 Mar; 228(3):669-75. PubMed ID: 6707916 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial. Webster L; Hjelmström P; Sumner M; Gunderson EW J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785 [TBL] [Abstract][Full Text] [Related]
38. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Mintzer MZ; Correia CJ; Strain EC Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664 [TBL] [Abstract][Full Text] [Related]
39. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting. Amato P Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244 [TBL] [Abstract][Full Text] [Related]
40. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder. Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]